Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

MISSISSAUGA, Canada, Dec. 12 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its majority-owned subsidiary CIMYM BioSciences Inc. received a milestone payment from its licensee Innogene Kalbiotech Ltd (IGK) in recognition of the recent marketing approval of nimotuzumab in the Philippines and Indonesia. IGK is the biotech subsidiary of P.T Kalbe Farma Tbk (Jakarta, Indonesia), one of the largest pharmaceutical companies in the region with more than 8,100 employees and annual revenues exceeding US$300 million.

"With the addition of the Philippines and Indonesia, nimotuzumab has now received marketing approval in twelve countries. Demand for novel medicines is growing rapidly in the emerging markets of the world and nimotuzumab is well positioned to become a key cancer therapeutic in these territories due to its unique safety profile compared with the other EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "Highlighting this competitive advantage, reports have increased in frequency describing toxicities associated with the combination of the other EGFR drugs and radiation. In addition to Grade III/IV rash, Grade IV radiation dermatitis, another serious and debilitating toxicity, has recently been reported affecting approximately 28% of patients treated with a currently marketed EGFR-targeting antibody together with radiation while absent in patients treated with radiation alone."

In none of the clinical trials of nimotuzumab to date, to YM's knowledge, have any of the patients developed Grade III/IV acneiform rash, also a severe and dose-limiting side-effect observed in all of the other antibodies and with small molecules targeting the EGF tyrosine kinase signaling pathway. Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxici
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:8/21/2014)... August 21, 2014 It's a terrible thing ... road to a serious substance abuse issue. When that happens ... of action is getting reliable help from the qualified substance ... right facility isn’t always easy for those young adults living ... a significant addiction issue. , Thankfully there is a ...
(Date:8/21/2014)... Angeles, CA (PRWEB) August 21, 2014 Sleep ... doctors across the U.S. This provides doctors with a convenient ... who find a doctor are that much closer to finding ... condition have no idea they are experiencing this sleep ... not receive treatment at all. , Thanks to Sleep Apnea ...
(Date:8/21/2014)... ERT, a leading global ... efficacy endpoint data collection, today opened registration ... Maximizing Product Value with Optimized Endpoints. ... biopharmaceutical developers to network with leading researchers ... developing, implementing, and justifying effective strategies for ...
(Date:8/21/2014)... shirt do we put on in the morning? Do we ... joint do we want to buy lunch? We make hundreds ... have a minimal impact, it is extremely important for our ... as possible. People with ADHD often find this difficult, however. ... which bring a prompt but smaller reward instead of making ...
(Date:8/21/2014)... 2014 Bedros Keuilian’s Annual Fitness Business Summit ... attended by many people already earning seven-figure incomes. But his ... usually only open to the owners of Keuilian’s own international ... year’s Fit Body Boot Camp World Conference will also be ... fitness boot camp or are struggling with their own ...
Breaking Medicine News(10 mins):Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Sleep Apnea Doctors US is Now Offering Complimentary Listings to Sleep Apnea Doctors Across the United States 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3
... 22 Weight Watchers,International, Inc. (NYSE: WTW ) ... a written plan for the purpose of,selling limited amounts ... adopted in accordance with Rule 10b5-1 of the Securities ... to exercise stock,options to diversify his holdings for financial ...
... in hemodialysis patients , , FRIDAY, Feb. 22 (HealthDay News) ... control in people with diabetes gives inaccurate results for ... Hemodialysis, used to treat patients with kidney failure, involves ... machine. , This Wake Forest University Baptist Medical ...
... The following statement,was issued today by William ... Kids:, The Nebraska Legislature has delivered a ... breathe clean air by passing legislation to make,all ... urge Governor Dave Heineman to sign into law ...
... ATLANTA, Feb. 22 Rarely written about, seldom spoken,of, ... the,lives of an astonishing 40% of women and 25% ... and turn what once were ordinary,tasks and activities into ... of 3, found the varicose veins significantly,affected her life ...
... Women of the United States, we,double dare you! ... your risk of cardiovascular disease., Who,s laying down ... the,American Heart Association has challenged women across the country ... to reduce their risks.,RealAge.com, the nation,s leading healthy-lifestyle Web ...
... Mo. More than $1.1 billion a year is spent ... Missouri study reports the state has a rising number of ... with hunger. The MU Interdisciplinary Center for Food Security has ... first Missouri Hunger Atlas details the distribution of hunger in ...
Cached Medicine News:Health News:Weight Watchers COO Adopts 10b5-1 Trading Plan 2Health News:Current Blood Sugar Control Test Results 'Inaccurate' 2Health News:Approval of Nebraska Smoke-Free Legislation is Historic Win for Health 2Health News:Beyond Vanity: New Treatment Brings Relief to Women After Years of Silent Suffering 2Health News:American Heart Month Double Dares Women to Beat Health Foes 2Health News:MU research team releases first Missouri Hunger Atlas 2
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... manufactured for use as a diluent for ... is for use on the Coulter® Counter ... IV, V, VI with three-part differential and ... The shelf life is two years from ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... 12 Plus Retics is a 5-part differential ... for the Abbott CELL-DYN 3200, 3500, 3700 ... also contains nucleated red blood cells that ... CELL-DYN 4000. The assay contains automated and ...
Medicine Products: